Anne Lesage Sells 3,700 Shares of Pharvaris (NASDAQ:PHVS) Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Anne Lesage sold 3,700 shares of the firm’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $30.08, for a total transaction of $111,296.00. Following the sale, the insider directly owned 56,450 shares in the company, valued at $1,698,016. This represents a 6.15% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Anne Lesage also recently made the following trade(s):

• On Thursday, April 30th, Anne Lesage sold 19,200 shares of Pharvaris stock. The stock was sold at an average price of $30.26, for a total transaction of $580,992.00.
• On Thursday, April 30th, Anne Lesage sold 21,700 shares of Pharvaris stock. The stock was sold at an average price of $30.26, for a total transaction of $656,642.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,000 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $210,350.00.
• On Wednesday, April 22nd, Anne Lesage sold 7,500 shares of Pharvaris stock. The stock was sold at an average price of $30.05, for a total transaction of $225,375.00.
• On Thursday, April 23rd, Anne Lesage sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.

Pharvaris Stock Performance

PHVS opened at $29.44 on Friday. The company’s 50 day simple moving average is $27.62 and its 200 day simple moving average is $26.06. Pharvaris N.V. has a 1 year low of $14.59 and a 1 year high of $31.14. The stock has a market capitalization of $1.93 billion, a PE ratio of -8.74 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS) last released its earnings results on Friday, April 3rd. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.69) by ($0.15). As a group, sell-side analysts expect that Pharvaris N.V. will post -3.19 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Seven Fleet Capital Management LP acquired a new position in Pharvaris during the fourth quarter valued at approximately $1,536,000. XTX Topco Ltd lifted its position in Pharvaris by 126.1% during the fourth quarter. XTX Topco Ltd now owns 18,568 shares of the company’s stock valued at $515,000 after buying an additional 10,355 shares in the last quarter. Ikarian Capital LLC lifted its position in Pharvaris by 131.7% during the fourth quarter. Ikarian Capital LLC now owns 486,856 shares of the company’s stock valued at $13,510,000 after buying an additional 276,691 shares in the last quarter. Virtus Investment Advisers LLC lifted its position in shares of Pharvaris by 66.7% during the fourth quarter. Virtus Investment Advisers LLC now owns 11,011 shares of the company’s stock worth $306,000 after purchasing an additional 4,407 shares in the last quarter. Finally, SummitTX Capital L.P. acquired a new position in shares of Pharvaris during the fourth quarter worth $634,000.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Insiders still retain large, meaningful stakes after the sales, which can indicate alignment with shareholders and limit the likelihood of continued big disposals. Examples: director Johannes Schikan remains a large shareholder (~355k shares after sales) and others still hold six‑figure stakes. SEC Filing
• Neutral Sentiment: Commentary noting that director sales may matter less than upcoming company catalysts — suggests investors should watch near‑term clinical/regulatory milestones rather than focus only on the trades. For Pharvaris Investors, the Director’s Sale Matters Less Than What’s Coming Next
• Negative Sentiment: Anne Lesage sold multiple blocks (3,700; 19,200; 21,700 shares) across April 29–30 at ≈$30.08–$30.26, reducing her position by as much as ~27.8% in filings and generating >$1.34M in proceeds — a signal that prompted selling pressure. SEC Filing
• Negative Sentiment: Peng Lu executed two sales (3,733 and 15,000 shares) on April 29–30 at ≈$30.06–$30.24, cutting ownership by up to ~18.5% and raising roughly $565.8k — another substantial insider liquidity event. SEC Filing
• Negative Sentiment: Director Johannes Gerardus Chri Schikan sold two blocks (3,830 and 29,070 shares) on April 29–30 at ≈$30.07–$30.32, a ~7.6% cut in his holdings and ~ $996.6k in disclosed proceeds — adding to the overall sell pressure. SEC Filing

Analysts Set New Price Targets

Several equities research analysts recently issued reports on PHVS shares. Wall Street Zen cut shares of Pharvaris from a “sell” rating to a “strong sell” rating in a research report on Monday, April 13th. Royal Bank Of Canada decreased their target price on shares of Pharvaris from $52.00 to $51.00 and set an “outperform” rating on the stock in a research report on Monday, April 6th. Wedbush raised their target price on shares of Pharvaris from $41.00 to $42.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 7th. HC Wainwright restated a “buy” rating and issued a $60.00 price target on shares of Pharvaris in a report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a research report on Tuesday, April 21st. Eleven analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $42.73.

About Pharvaris

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.